enous ligands, NPW30 and NPW23, the N-terminal sequence of which binds with similar affinity to NPBWR1 and NPBWR2 [2] . They also predicted that intracerebroventricular (icv) administration of these peptides would influence hypothalamic function, and found that icv administration of NPW23 significantly increased food intake and prolactin (PRL) secretion in rats. Similarly, Baker et al. reported that NPW23 decreased GH and stimulated PRL and corticosterone secretion in rats [3] . Furthermore, icv injection of NPW activates the hypothalamic-pituitary-adrenal (HPA) axis, as determined by plasma corticosterone levels.
We hypothesized that NPW activates the HPA axis via corticotrophin-releasing factor (CRF) and/or arginine vasopressin (AVP). To investigate the mechanism by which NPW activates the HPA axis, we performed in vitro and in vivo experiments in this study. free culture medium alone or medium containing 1 pM to 10 nM of NPW with or without 40 pM ACTH for 4 h to measure corticosterone secretion. After incubation, the medium was transferred to a conical tube and centrifuged at 1500 ×g at 4°C for 5 min. The resulting supernatant was stored at -20°C until corticosterone determination.
Primary culture of rat anterior pituitary cells
Anterior pituitary cells were dispersed with 0.2% collagenase and 40 µg/mL DNase 1. After dispersion, 10 5 cells in 0.5 mL culture medium described above were plated in 48-well tissue culture plates (Costar, Cambridge, MA). The cells were maintained in static monolayer culture for 4 days in a humidified incubator under a 5% CO 2 /95% air atmosphere at 37°C. On day 4 of culture, the cells were washed three times with 0.5 mL of serum-free culture medium and then incubated with 0.5 mL of serum-free culture medium alone or medium containing 1 pM to 10 nM of NPW with or without 1 nM r/h CRF for 4 h to measure ACTH release. After incubation, the medium was transferred to a conical tube and centrifuged at 1500 ×g at 4°C for 5 min. The supernatant was stored at -20°C until ACTH determination.
Intravenous (iv) injection of NPW
Under sodium pentobarbital anesthesia (50 mg/ kg, intraperitoneal), an indwelling jugular vein cannula (PE-50, Becton, Dickinson and Company, NJ, USA) was implanted, and exteriorized at the back of the neck, filled with heparinized saline (100 U/mL) and tied shut. On the following day, an extension tube (PE-50) was attached to the jugular cannula to facilitate blood sampling and the rats were left undisturbed for 60 min. Then, an initial blood sample was withdrawn from the jugular vein without disturbing the animal. Immediately after collecting the initial blood sample, 200 μL of isotonic saline without or with 2.5 or 25 nmol NPW was administered iv via the indwelling jugular vein cannula. Blood samples were collected at 15, 30 and 60 min after iv injections. Immediately after each blood sampling, the same volume of saline was injected.
Icv injection of NPW
Under sodium pentobarbital anesthesia (50 mg/kg, intraperitoneal), the rats were placed in a Narishige stereotaxic apparatus with the skull flat between the
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Reagents
NPW30 (rat) and rat/human CRF (r/h CRF) were purchased from Peptide Institute (Osaka, Japan). We used NPW30 not NPW23, because of its availability. Astressin (a CRF receptor antagonist), [1-(β-mercapto-β, β-cyclopentamethylenepropionic acid),2-(ο-methyl)tyrosine]-arg-vasopressin (V1a/V1b receptor antagonist) and ACTH were purchased from Bachem (Bubendorf, Switzerland). All bioactive peptides were dissolved in 0.1 N HCl at 100 µM as a stock solution, aliquoted, freeze-dried and stored at -80°C. 
Animals
All experiments were conducted under the guidelines of the Ethical Committee of Animal Experiments of the Hamamatsu University School of Medicine. Male Sprague-Dawley rats weighing 160-180 g (6 weeks old) were obtained from JAPAN SLC Inc. (Hamamatsu, Japan) and housed in a temperature-controlled room (24°C) for 1 week before each experiment, with lights on from 0700-1900 h daily. Rats were given free access to standard rat chow and water throughout the studies.
In vivo experiments were started 3-4 h after lights on.
Primary culture of rat adrenal cells
Adrenal fasciculata-reticularis cells were dispersed with 0.1% collagenase and 20 µg/mL DNase 1. After dispersion, 10 5 cells in 0.5 mL culture medium [Medium 199 supplemented with 10 mM HEPES, 10 mM NaHCO 3 , 0.1% BSA, 20 U/mL penicillin, 20 U/ mL streptomycin, 0.05 mg/mL amphotericin B and 10% FCS] were plated on 48-well tissue culture plates. Cells were maintained in static monolayer culture for 3 days in a humidified incubator under a 5% CO 2 /95% air atmosphere at 37°C. On day 3 of culture, the cells were washed three times with 0.5 mL of serum-free culture medium and then incubated with 0.5 mL of serum-of isotonic saline icv.
All blood samples (300 µL) were taken and replaced with an equal volume of isotonic saline. Blood samples were transferred to tubes containing 10 µg/30 µL EDTA-2Na, kept on ice at 4°C until plasma separation (3000 ×g for 3 min) and stored at -20°C until required for assays.
ACTH radioimmunoassay (RIA)
The ACTH-RIA for in vitro and in vivo samples was performed using rabbit antiserum against ACTH . The characteristics of the assay have been reported elsewhere [4] . In brief, synthetic ACTH 1-39 was radio-iodinated with Na 125 I using the chloramine T method. The labeled ACTH 1-39 was purified with a Sephadex G75 superfine column (1 × 50 cm). Medium samples were diluted 1:20 in RIA buffer (63 mM phosphate buffer, pH 7.4, containing 0.1% Triton X-100, 500 kallikrein inactivator U/mL Trasylol, 1 mM EDTA, 0.02% sodium azide), and plasma was diluted 1:10 in RIA buffer containing 3.5% BSA. For the RIA, 100 μL of standard ACTH 1-39 or sample was incubated with 100 μL of antiserum (final dilution 1:15,000) at 4°C. After incubation for 1 day, 100 μL of labeled ACTH 1-39 was added and incubated for 1 day at 4°C. The antibody-bound and free peptides were separated by incubation with 100 μL of secondary antibody (anti-rabbit-globulin goat serum) and 100 μL of 25% polyethylene glycol for 6 h at 4°C, followed by centrifugation at 4500 rpm for 20 min at 4°C. The radioactivity bound to antibody was counted in a γ counter (ARC-7010, Aloka, Tokyo, Japan). Samples were assayed in duplicate. The minimum detection limit of the assay was 0.5 pg/assay tube.
Corticosterone RIA
The corticosterone RIA was performed using rabbit antiserum against corticosterone-3-CMO-BSA. The characteristics of the assay have been reported elsewhere [5] . In brief, samples were diluted 1:10 in RIA buffer containing 0.1% BSA and subjected to RIA. For RIA, a mixture comprising 100 μL of standard corticosterone or samples, 100 μL of antiserum (initial dilution, 1:15,000) and 100 μL of labeled 125 I-corticosterone (MP Biomedicals, Solon, OH, USA) was incubated for 24 h at 4°C. The antibody-bound and free corticosterone were separated by adding 100 μL of 0.5% bovine γ-globulin and 400 μL of 25% polyethylene glycol. Samples were assayed in duplicate. The minimum detection limit of the assay was 0.1 ng/assay tube. bregma and lambda. One hole was made on the left side of the skull (0.8 mm posterior and 1.6 mm left from the bregma) with a dental drill. A stainless-steel single guide cannula (C313G, Plastics One Inc., Roanoke, VA, USA) was implanted into the lateral cerebroventricle (anteroposterior 0.8 mm, mediolateral 1.6 mm, dorsoventral 4.1 mm relative to the bregma, according to the atlas of Paxinos and Watson, 1986) under the guidance of a stainless-steel wire attached in a horizontal position to a stereotaxic holder. Two additional screws were placed on the skull and served as anchors, and the entire assembly was attached to the skull with dental resin cement (GC UNIFAST ® ; GC Co., Tokyo, Japan). A removable stainless-steel stylet (C313DC, Plastics One Inc., VA, USA) was placed into the guide cannula. Rats were placed in isolation after surgery. At least 5 days later, after the animals had returned to their preoperative body weights, an indwelling jugular vein cannula was implanted again under sodium pentobarbital anesthesia. The jugular cannula was exteriorized at the back of the neck and filled with heparinized saline and tied shut as described above. The following day, an extension tube (PE-50) was attached to the jugular cannula to facilitate blood sampling and rats were left undisturbed for 60 min. Then, an initial blood sample was withdrawn from the jugular vein without disturbing the animal. Immediately after collecting the initial blood sample, an extension tube (PE-10) was attached to the lateral cerebroventricular cannula to administer the test substances, and 10 µL of isotonic saline without or with 2.5 or 5.0 nmol NPW was administered via the lateral cerebroventricular cannula (icv). Blood samples were collected at 15, 30 and 60 min after the icv injections.
Icv injection of NPW after pretreatment with vehicle, a CRF receptor antagonist or an AVP receptor antagonist
A lateral cerebroventricular cannula and an indwelling jugular vein cannula were implanted into rats as described above. The rats were left undisturbed for 60 min before each experiment. After collecting an initial blood sample (-15 min), 200 µL of isotonic saline without or with 20 µg of astressin (100 µg/kg) or 5 µg of a V1a/V1b receptor antagonist (25 µg/kg) was administered iv. Fifteen minutes later, a second (0 min) blood sample was collected and the animals received an icv injection of 10 µL isotonic saline containing 2.5 nmol NPW. Blood samples were collected at 15, 30 and 60 min after the icv injection. For a control group, rats received 200 µL of isotonic saline iv followed by 10 µL
Statistical analysis
All results are expressed as means ± SEM. Statistical analysis was performed by Student's two-tailed unpaired t-test, or by one-way analysis of variance (ANOVA)
Results
Effects of NPW on corticosterone release from dispersed adrenal fasciculata-reticularis cells NPW at concentrations of 1.0 pM to 10 nM did not affect corticosterone release from dispersed adrenal fasciculata-reticularis cells (p>0.05, Fig. 1 ). By contrast, 40 pM ACTH increased corticosterone secretion compared with vehicle alone (14.2 ± 2.2 vs. 1.50 ± 0.25 ng/well, p<0.001, Fig. 1 ). Meanwhile, ACTHstimulated corticosterone release from these cells was not affected by NPW at any of the concentrations tested (p>0.05, Fig. 1 ).
Effects of NPW on ACTH release from dispersed anterior pituitary cells
NPW at concentrations of 1.0 pM to 10 nM did not affect ACTH release from dispersed anterior pituitary cells (p>0.05, Fig. 2 ). CRF increased ACTH release compared with vehicle alone (7.36 ± 0.58 vs. 1.95 ± 0.23 pg/well, p<0.001, Fig. 2 ). However, CRFstimulated ACTH release from anterior pituitary cells was not affected by NPW at any of the concentrations tested (p>0.05, Fig. 2 ).
Effects of iv administration of NPW on plasma ACTH release
The iv injection of saline alone did not affect plasma ACTH levels in conscious, unrestrained male rats (p>0.05, Fig. 3) . Similarly, iv injection of 2.5 and 25 nmol NPW did not affect plasma ACTH levels (p>0.05, Fig. 3 ).
Effects of icv administration of NPW on plasma ACTH release
The icv injection of saline alone did not affect plasma ACTH levels in conscious, unrestrained rats (p>0.05, Fig. 4 ). On the other hand, icv administration of 2.5 nmol NPW significantly increased plasma ACTH levels at 15 and 30 min (0 min, 169 ± 41 pg/mL; 15 min, 1170 ± 204 pg/mL, p<0.01; 30 min, 981 ± 187 pg/mL, The stimulatory effects of 2.5 and 5.0 nmol NPW on ACTH secretion reached a peak at 15 min, and dosedependent effects of icv administration of NPW were demonstrated. In addition, rats injected with NPW exhibited more pronounced grooming, gnashing and hyperactivity behaviors than rats injected with vehicle, although statistical analysis was not performed.
Effects of icv injection of NPW on plasma ACTH release in rats pretreated with a CRF receptor antagonist or an AVP receptor antagonist
In rats pretreated with saline followed by icv injection of isotonic saline alone, the plasma ACTH levels were unchanged (p>0.05, Fig. 5 ). By contrast, the plasma ACTH levels increased in conscious/unrestrained male rats pretreated with vehicle followed by icv injection of 2.5 nmol NPW. Of note, the plasma ACTH levels were significantly increased at 15, 30 and 60 min (15 min, 1532 ± 343 pg/mL, p<0.01; 30 min, 1214 ± 139 pg/mL, p<0.01; 60 min, 797 ± 126 pg/mL, p<0.05, Fig. 5 ) ver- ticosterone production in dispersed zona fasciculata/ reticularis cells or adrenal quarters containing cortical and medullary tissues [18, 19] . In vivo, we could evaluate the kinetic change of plasma ACTH levels from the administration of NPW23 to the end of blood sampling under the constantly unrestrained condition, that differed from previous studies [18, 19] . These earlier findings and the present results suggest that the effect of NPW on the HPA axis does not involve the peripheral adrenal or pituitary sites, whereas NPBWR1 mRNA has been shown to be expressed in the pituitary and adrenal cortex [6, 18, 20] .
The findings with icv administration of NPW indicate that NPW activates the HPA axis by regulating plasma ACTH levels. Furthermore, the elevations in plasma ACTH levels induced by icv NPW reached a peak at 15 min, and dose-dependent effects of icv NPW were demonstrated.
In this study, we found that the increase in plasma ACTH levels induced by icv NPW was blocked by the CRF receptor antagonist, but not by the V1a/V1b receptor antagonist. The dose of V1a/V1b receptor antagonist was enough to inhibit endogenous AVP, because its dose was higher than that previously reported [21] . This suggests that central administration of NPW activates the HPA axis via CRF, but not via AVP. NPBWR1 expression in the human brain was confirmed by northern blotting, and in situ hybridization confirmed gene expression in hypothalamic areas of the mouse brain [1] . In 1999, the same group reported an even broader distribution of NPBWR1 in the rat brain than had been observed in the mouse and human brains. Within the hypothalamus, gene transcripts for these receptors were observed in the PVN and the supraoptic nucleus, the arcuate nucleus, and in the ventromedial and dorsomedial nuclei, as well as in the suprachiasmatic nucleus [17] . Furthermore, high levels of NPBWR1 mRNA and binding signals were found in the rat brain amygdala, suprachiasmatic nuclei and the ventral tuberomamillary nuclei [22, 23] . All of these nuclei play important roles in the neuroendocrine regulation of anterior pituitary hormone secretion.
The abundant expression of NPBWR1 in the PVN suggests that NPW acts on CRF neurons in the PVN to release CRF from the hypothalamus to the median eminence, and that CRF subsequently activates CRF receptor 1 in the anterior pituitary to release ACTH through the portal vein. Stress signals are forwarded from the affective system, the cerebral cortex and the sus 0 min (136 ± 53 pg/mL). Pretreatment with the CRF receptor antagonist did not affect plasma ACTH levels before icv NPW injection, as compared with pretreatment with vehicle (p>0.05, Fig. 5 ). Pretreatment with the CRF receptor antagonist inhibited the increase in plasma ACTH levels in response to icv NPW at 15 min (453 ± 176 vs. 1532 ± 343 pg/mL, p<0.05, Fig. 5 ) and at 30 min (564 ± 147 vs. 1214 ± 147 pg/mL, p<0.05, Fig.  5 ). However, pretreatment with the AVP receptor antagonist did not affect the icv NPW-induced increase in plasma ACTH levels at any time-point (p>0.05, Fig. 5 ).
Discussion
NPW was originally identified as an endogenous ligand for the orphan G-protein coupled receptors, NPBWR1 and NPBWR2. It has been reported that rat NPW mRNA is expressed in the hypothalamus, pituitary gland and adrenal gland [6] . NPW is thought to play a role in the regulation of feeding behavior, energy homeostasis [2, [7] [8] [9] , neuroendocrine regulation [2, 3, 10] , autonomic regulation [11] and inflammatory pain [12, 13] . In terms of its neuroendocrine roles, it has been reported that icv administration of NPW elevates plasma PRL and corticosterone levels and lowers GH levels [3] . The discrete expression of NPBWR1 in the hypothalamus [1] suggests a potential role in regulating stress responses, emotion, anxiety and fear. ACTH release from the anterior pituitary is regulated by hypothalamic factors such as CRF and AVP [14] . NPBWR1 mRNA was reported to be expressed in the paraventricular nucleus (PVN) [15] [16] [17] , and both an NPW transcript and NPW-immunoreactive neurons were observed in the parvocellular division of PVN where CRF and AVP neurons coexist [7] . They suggest that activation of the HPA axis by NPW may occur via CRF or AVP. Thus, we investigated the mechanisms involved in the activatio0n of the HPA axis by NPW.
None of the concentrations of NPW tested here affected corticosterone or ACTH release in primary cultures of rat adrenal and pituitary cells, respectively. Similarly, iv administration of NPW did not affect the plasma ACTH levels, and there were no significant differences between the vehicle and NPW groups in vivo. In vitro, these results are consistent with those reported by other investigators [3, 18, 19] . NPW23 at 1 pM to 100 nM did not significantly affect the release of ACTH from dispersed anterior pituitary cells [3] . Similarly, NPW23 did not affect basal or ACTH-stimulated cor-to 90 min after iv injection [25] . We also suggested that AVP was not involved in the NPW-mediated increase in plasma ACTH, because pretreatment with the V1a/b antagonist did not inhibit the increase in plasma ACTH levels in response to icv NPW. These findings suggest that central NPW stimulates ACTH secretion from the pituitary, mainly through hypothalamic CRF, but not through AVP. Furthermore, endogenous urocortins do not affect ACTH release [26, 27] suggesting that central NPW stimulates ACTH secretion mediated by CRF through the CRF1 receptor.
In conclusion, Central NPW may play an important role in the activation of the HPA axis by inducing hypothalamic CRF, but not AVP.
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This study was supported, in part, by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan. limbic system to CRF neurons in the PVN; thus, we suggest that NPW plays an important role in this process. The plasma ACTH levels rapidly reached a peak at 15 min after icv administration of NPW, which is consistent with the location of the PVN, adjacent to the cerebral ventricles. It was reported that pretreatment with a CRF antagonist weakens the effect of icv NPW on the increase in plasma corticosterone levels. However, the CRF antagonist alone seemed to suppress the corticosterone levels before NPW administration, although this was not statistically significant. In addition, the incremental ratio and the increased corticosterone levels after icv administration of NPW did not appear to differ between the vehicle-and CRF antagonist-treated groups [24] . On the other hand, our results clearly show that the CRF antagonist did not affect basal ACTH levels, but did decrease the change in plasma ACTH levels in response to icv administration of NPW. We found no significant decrease in plasma ACTH levels at 60 min, because the effects of the CRF antagonist, astressin, tend to weaken from 45
